Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans

FierceBiotechCould engaging the immune system improve AML outcomes?

FierceBiotechWhy AI is changing clinical development

FierceBiotechManaging complexity across biopharma modalities

NINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBox

Endpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects

IlluminaIllumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo Finance

FierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

MIURA CO.,LTD.Miura Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:MIURF) 2026-06-06 - Seeking Alpha

10x Genomics News10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed - simplywall.st

FierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes

Clinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune Disease

CellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation